PortfoliosLab logoPortfoliosLab logo
Repligen Corporation (RGEN)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US7599161095
CUSIP
759916109
IPO Date
Mar 26, 1990

Highlights

Market Cap
$6.66B
Enterprise Value
$6.80B
EPS (TTM)
$0.86
PE Ratio
136.99
PEG Ratio
5.31
Total Revenue (TTM)
$738.25M
Gross Profit (TTM)
$386.41M
EBITDA (TTM)
$161.65M
Year Range
$102.97 - $175.77
Target Price
$181.43
ROA (TTM)
1.65%
ROE (TTM)
2.31%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Repligen Corporation

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Repligen Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Repligen Corporation (RGEN) has returned -28.10% so far this year and -7.40% over the past 12 months. Looking at the last ten years, RGEN has achieved an annualized return of 15.91%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.


Repligen Corporation

1D
5.68%
1M
-8.48%
YTD
-28.10%
6M
-11.86%
1Y
-7.40%
3Y*
-11.22%
5Y*
-9.63%
10Y*
15.91%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Mar 26, 1990, RGEN's average daily return is +0.14%, while the average monthly return is +2.21%. At this rate, your investment would double in approximately 2.6 years.

Historically, 50% of months were positive and 50% were negative. The best month was Feb 2000 with a return of +191.8%, while the worst month was Dec 1994 at -44.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.

On a daily basis, RGEN closed higher 45% of trading days. The best single day was May 4, 1998 with a return of +104.2%, while the worst single day was Jan 5, 2004 at -42.6%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-8.84%-13.82%-8.48%-28.10%
202515.47%-4.18%-20.11%8.45%-14.44%5.34%-5.88%4.48%9.28%11.51%14.73%-4.19%13.84%
20245.34%2.42%-5.19%-10.72%-9.20%-15.45%32.75%-9.81%-1.40%-9.78%12.12%-4.38%-19.94%
20239.44%-5.90%-3.45%-9.94%10.74%-15.76%21.28%1.37%-8.57%-15.38%16.86%14.34%6.20%
2022-25.11%-0.83%-4.38%-16.40%4.60%-1.26%31.38%2.82%-14.71%-2.47%-2.00%-5.33%-36.07%
20214.37%6.20%-8.47%8.90%-13.75%9.31%23.08%15.17%2.12%0.52%-1.38%-7.56%38.20%

Benchmark Metrics

Repligen Corporation has an annualized alpha of 30.49%, beta of 0.83, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since March 27, 1990.

  • This stock participated in 106.70% of S&P 500 Index downside but only 98.10% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
30.49%
Beta
0.83
0.04
Upside Capture
98.10%
Downside Capture
106.70%

Return for Risk

Risk / Return Rank

RGEN ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.


RGEN Risk / Return Rank: 3131
Overall Rank
RGEN Sharpe Ratio Rank: 3333
Sharpe Ratio Rank
RGEN Sortino Ratio Rank: 3131
Sortino Ratio Rank
RGEN Omega Ratio Rank: 3131
Omega Ratio Rank
RGEN Calmar Ratio Rank: 3030
Calmar Ratio Rank
RGEN Martin Ratio Rank: 2828
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Repligen Corporation (RGEN) and compare them to a chosen benchmark (S&P 500 Index).


RGENBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.16

0.90

-1.05

Sortino ratio

Return per unit of downside risk

0.11

1.39

-1.27

Omega ratio

Gain probability vs. loss probability

1.01

1.21

-0.20

Calmar ratio

Return relative to maximum drawdown

-0.32

1.40

-1.72

Martin ratio

Return relative to average drawdown

-0.76

6.61

-7.37

Explore RGEN risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Repligen Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Repligen Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Repligen Corporation was 98.28%, occurring on Jul 17, 1996. Recovery took 4695 trading sessions.

The current Repligen Corporation drawdown is 63.66%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.28%Oct 23, 19911197Jul 17, 19964695Mar 13, 20155892
-71.01%Jun 15, 199074Sep 28, 1990246Sep 19, 1991320
-66.41%Sep 24, 2021888Apr 8, 2025
-50.33%Jul 8, 2015149Feb 8, 2016347Jun 23, 2017496
-32.87%Sep 19, 201799Feb 8, 201893Jun 22, 2018192

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Repligen Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Repligen Corporation is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for RGEN, comparing it with other companies in the Medical Instruments & Supplies industry. Currently, RGEN has a P/E ratio of 137.0. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for RGEN compared to other companies in the Medical Instruments & Supplies industry. RGEN currently has a PEG ratio of 5.3. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for RGEN relative to other companies in the Medical Instruments & Supplies industry. Currently, RGEN has a P/S ratio of 9.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for RGEN in comparison with other companies in the Medical Instruments & Supplies industry. Currently, RGEN has a P/B value of 3.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items